Prevention
Detection
Diagnosis and Treatment
BGI Real Solution Joint-Laboratory
A 20-year-old brand
built on expertise
With 2.1 million new cases worldwide, breast cancer is the leading cancer among women both in terms of incidence and mortality.
The early diagnosis rate of breast cancer is relatively low (15.7%) [1].
The mean age at diagnosis is lower, in the range of 45 to 55 years[1].
BRCA1 and BRCA2 are tumor suppressor genes that play a significant role in DNA damage repair.
When a mutation occurs, the BRCA1/2 genes can' t work properly, thus increasing a woman's breast cancer susceptibility 5-fold and ovarian cancer by 10 to 30 times[2].
of BRCA1/2 mutation carriers have no family
history of breast/ovarian cancer
Detection of 6,000+ variants in the entire exonic region of BRCA1 and BRCA2
Those with an unhealthy lifestyle, high stress level or endocrine disorders
Women with early menarche, who have had no children, and late child bearers who did not breastfeed or with late menopause
Those with a family history of breast/ovarian cancer
Women who are concerned about their breast and ovarian health
Before sampling, please read the instructions for use of the sampling kit and make sure that the materials are not damaged and within the expiration date.
This test has been clinically proven to be effective. Self-sampling using the materials included in the kit and following the instructions is comparable to hospital sampling.
No, it doesn't. A test result of "high-risk" only means that you're at high risk of developing breast/ovarian cancer. Please follow the advice of your genetic counselor to maintain a healthy lifestyle or adopt medical interventions to reduce the risk of developing cancer.
It has been found that deleterious mutations in BRCA1/2 can be detected in phenotypically healthy people with no family history of BRCA1/2 mutations, which will increase their risk of subsequent breast or ovarian cancer. Therefore, in addition to high-risk groups with a family history of BRCA1/2 mutations, healthy people also need to test for susceptibility genes for the purpose of early prevention and timely intervention in breast/ovarian cancer.
Lei Fan et al. Current status of breast cancer in China (review). Lancet Oncol, June 15, 2014.
Editorial team of the Chinese Expert Consensus on BRCA Gene Testing Process Based on Next-Generation Sequencing Technology. Chinese Expert Consensus on BRCA Gene Testing Process Based on Next-Generation Sequencing Technology. Chinese Journal of Pathology, Vol. 47, No. 6, June 2018.
Kandamurugu Manickam, et al., Exome Sequencing–Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants, JAMA Network Open. 2018;1(5):e182140. doi:10.1001/jamanetworkopen.2018.2140
Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017.